EpiPen prices far outpace cost sharing:

  • Mylan has increased their list price from $100 in 2009 to over $600 in 2016
  • Over the same period, most people would have only had their fixed copay increase from $27 to $31 while coinsurance has held steady at approximately 25-27%
  • The overall average patient cost share paid for EpiPens—including both copays and coinsurance—has decreased from 26% of list price in 2009 to 11% in 2016

View the infographic.